Menu
Back to Journals » Clinical Interventions in Aging » Volume 8
Rifampicin-resistant Mycobacterium leprae in an elderly leprosy patient in the People's Republic of China
Authors Yu M, Wu K, Pei B, Yang D, Wang Q, Wang H , Shen J, Yan L, Zhang G
Received 9 June 2013
Accepted for publication 24 July 2013
Published 21 August 2013 Volume 2013:8 Pages 1097—1099
DOI https://doi.org/10.2147/CIA.S49653
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Meiwen Yu,1,* Kan Wu,1,* Bing Pei,2 Degang Yang,2 Qiulin Wang,1 Hongsheng Wang,1 Jianping Shen,1 Liangbing Yan,1 Guochen Zhang1
1Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for STD and Leprosy Control, China CDC, Nanjing, People's Republic of China; 2Department of Infectious Diseases, Shanghai Skin Disease Hospital, Shanghai, People's Republic of China
*These authors contributed equally to this work
Abstract: The reported number of registered leprosy patients worldwide declined with the introduction of multidrug therapy. However, the emergence of rifampicin resistance in leprosy patients engenders difficulties for an individual patient, and its dissemination could pose a threat to leprosy control. This study reports an elderly patient who was diagnosed with rifampicin-resistant lepromatous leprosy. This case indicates that inadequate treatment and poor compliance may eventually result in rifampicin resistance in Mycobacterium leprae and clinical relapse.
Keywords: leprosy, rifampicin, drug resistance, elderly patient
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.